RxDoctor Payments Data

Kimberly Yates, MD

Nephrology · Huntersville, NCNPI 1801836804

Payments from drug & device makers

$503in general payments, 2019–2025

Across 9 payments — averaging $55.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Travere Therapeutics, Inc.$116
  • Nxstage Medical, Inc.$113
  • Amgen$100
  • Genentech, Inc.$53
  • Vifor Pharma, Inc.$32
  • Baxter Healthcare$27
  • plus $62 from 3 others

What the payments were for

  • Food & beverage$45089%
  • Education$5311%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$503 in reported general payments places this provider in the 35th percentile of 366 nephrology providers in North Carolina.

See all nephrology providers in North Carolina

Medicare billing

Part B allowed, 2024
$264,537
Medicare patients
408
Services billed
3,661

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Thiola EcTiopronin24$101,134
FarxigaDapagliflozin Propanediol68$58,266
VelphoroSucroferric Oxyhydroxide18$53,297
JardianceEmpagliflozin31$36,434
AuryxiaFerric Citrate13$28,518
Sevelamer Carbonate41$9,839
VeltassaPatiromer Calcium Sorbitex15$8,142
Calcitriol249$3,704
Potassium Chloride54$1,411
Midodrine Hcl11$1,139
Torsemide28$980
Potassium Citrate ErPotassium Citrate12$789
Doxazosin Mesylate27$628
Losartan Potassium97$594
Lisinopril86$482

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$18$58,26668 claims
Fresenius USA Marketing, Inc.Velphoro$19$53,29718 claims
Akebia Therapeutics IncAuryxia$25$28,51813 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 366 nephrology providers in North Carolina.

Other nephrology in Huntersville

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →